Summary:
- This article discusses the diverging strategies of two major COVID-19 vaccine manufacturers, Moderna and BioNTech, as they navigate the evolving pandemic landscape.
- Moderna is focusing on developing a single vaccine that can protect against multiple variants of the COVID-19 virus, while BioNTech is pursuing a more flexible approach with customizable vaccines.
- The article highlights the challenges and opportunities these companies face in adapting their vaccine technologies to address the ongoing mutations of the SARS-CoV-2 virus and meet the changing needs of the global population.